Smith DL - Search Results

1

Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005.

Klein E, Smith DL, Laxminarayan R. Klein E, et al. Among authors: smith dl. Emerg Infect Dis. 2007 Dec;13(12):1840-6. doi: 10.3201/eid1312.070629. Emerg Infect Dis. 2007. PMID: 18258033 Free PMC article.

2

Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006.

Klein E, Smith DL, Laxminarayan R. Klein E, et al. Among authors: smith dl. Emerg Infect Dis. 2009 Dec;15(12):1925-30. doi: 10.3201/eid1512.081341. Emerg Infect Dis. 2009. PMID: 19961671 Free PMC article.

3

On the importance of incentives in hospital infection control spending.

Laxminarayan R, Smith DL, Real LA, Levin SA. Laxminarayan R, et al. Among authors: smith dl. Discov Med. 2005 Jun;5(27):303-8. Discov Med. 2005. PMID: 20704893 Free article.

4

The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study.

Klein EY, Sun L, Smith DL, Laxminarayan R. Klein EY, et al. Among authors: smith dl. Am J Epidemiol. 2013 Apr 1;177(7):666-74. doi: 10.1093/aje/kws273. Epub 2013 Feb 28. Am J Epidemiol. 2013. PMID: 23449778

5

Clinically immune hosts as a refuge for drug-sensitive malaria parasites.

Klein EY, Smith DL, Boni MF, Laxminarayan R. Klein EY, et al. Among authors: smith dl. Malar J. 2008 Apr 25;7:67. doi: 10.1186/1475-2875-7-67. Malar J. 2008. PMID: 18439283 Free PMC article.

6

Benefits of using multiple first-line therapies against malaria.

Boni MF, Smith DL, Laxminarayan R. Boni MF, et al. Among authors: smith dl. Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14216-21. doi: 10.1073/pnas.0804628105. Epub 2008 Sep 9. Proc Natl Acad Sci U S A. 2008. PMID: 18780786 Free PMC article.

7

"One-size-fits-all"? Optimizing treatment duration for bacterial infections.

Geli P, Laxminarayan R, Dunne M, Smith DL. Geli P, et al. Among authors: smith dl. PLoS One. 2012;7(1):e29838. doi: 10.1371/journal.pone.0029838. Epub 2012 Jan 11. PLoS One. 2012. PMID: 22253798 Free PMC article.

8

Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?

Laxminarayan R, Over M, Smith DL. Laxminarayan R, et al. Among authors: smith dl. Health Aff (Millwood). 2006 Mar-Apr;25(2):325-36. doi: 10.1377/hlthaff.25.2.325. Health Aff (Millwood). 2006. PMID: 16522574

9

Should new antimalarial drugs be subsidized?

Laxminarayan R, Parry IW, Smith DL, Klein EY. Laxminarayan R, et al. Among authors: smith dl. J Health Econ. 2010 May;29(3):445-56. doi: 10.1016/j.jhealeco.2010.03.002. Epub 2010 Mar 7. J Health Econ. 2010. PMID: 20381182

10

Bioeconomic analysis of child-targeted subsidies for artemisinin combination therapies: a cost-effectiveness analysis.

Klein EY, Smith DL, Cohen JM, Laxminarayan R. Klein EY, et al. Among authors: smith dl. J R Soc Interface. 2015 Jun 6;12(107):20141356. doi: 10.1098/rsif.2014.1356. J R Soc Interface. 2015. PMID: 25994293 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,621 results

Search Page